Year: 2010
Type: review
Study design: Observational Study
Abstract: The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C-11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid beta (Abeta) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C-11 Pittsburgh compound B PET, and CSF measurements of Abeta and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
Source: Alzheimer s & Dementia
Authors: Michael W. Weiner, Paul S. Aisen, Clifford R. Jack, William J. Jagust, John Q. Trojanowski, Leslie Shaw, Andrew J. Saykin, John C. Morris, Nigel Cairns, Laurel A. Beckett, Arthur Toga, Robert Green, Sarah Walter, Holly Soares, Peter Snyder, Eric Siemers, William Potter, Patricia E. Cole, Mark Schmidt, Alzheimer's Disease Neuroimaging Initiative
Institutions: San Francisco VA Medical Center, University of California, San Francisco, University of California San Diego, Mayo Clinic, University of California, Berkeley, University of Pennsylvania, Indiana University Bloomington, Indiana University, Washington University in St. Louis, University of California, Davis, University of California, Los Angeles, Boston University, Pfizer (United States), Brown University, Eli Lilly (United States), Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2001477615